CENP-V As a Potential Diagnostic Marker of Damage in Human Oocytes
Recruiting
Observational Study
Establish the Amount of CENPV Protein in Human Oocytes As a Diagnostic Tool Against Damage Caused by Ageing or by the Procedure of Vitrification of Oocytes
Advance Maternal Age
Vitrification and Thawing
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 45
- Sex
- Female
- Study type
- Observational
- Participants needed
- 160 (estimated)
- Sponsor
- Vida Recoletas Sevilla · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Proper chromosome segregation is essential to avoid aneuploidy, yet in mammalian oocytes it progressively fails in an age-dependent manner. The ageing population and the increasing age of parenthood are leading to a declined fertility. Proteins contributing to correct chromosome segregation and oocyte ageing are therefore of central interest. Mouse oocytes deficient in CENP-V are strongly impaired…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Group of patients with advanced maternal age (AMA): patients aged 36-45 years with AMA etiology as the main factor of infertility undergoing controlled ovarian stimulation.
* Group of patients with vitrification / thawing of their oocytes: patients between 18-45 years of age w…
Contacts